SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back


Speaker
Mark Stolar, MD
Associate Professor of Clinical Medicine
Feinberg School of Medicine
Northwestern University
Chicago, IL


Moderator
Gregg Sherman, MD
Family Practice
Plantation FL

Title
: Safely Achieving Goals in Type 2 Diabetes (T2D): The Role of Concentrated and Long-Acting Insulins
Activity/Course #:
: NCME356
Cost:
: Free
Release/Start Date:
: Aug 15 2018
Expiration Date:
: Aug 14 2019
Topics:
: Diabetes
Target Audience:
: Primary Care Providers
Format:
: Webcast
Estimated Time To Complete CME Activity:
: 1.0 Hour
Credit(s):
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.75 pharmacology hour(s)
Hardware/Software Requirements:
Program Summary

Type 2 diabetes mellitus (T2DM) is a major cause of morbidity and mortality in the United States, and its prevalence has been increasing. The disease is characterized by progressive failure of pancreatic β-cell function, leading to increasing difficulty in maintaining glycemic control. Even with multiple oral antidiabetic drugs, many patients need insulin therapy to achieve and maintain glycated hemoglobin (HbA1C) targets.

Early initiation of insulin therapy can reduce morbidity in patients with T2DM, but in practice, insulin therapy is underused. This educational activity will identify barriers to early insulin initiation, review currently available basal and ultrabasal insulins, and provide best practices to integrate strategies into practice, to improve the patient experience with insulin therapy.

This webcast was recorded live at the Emerging Challenges in Primary Care Live Virtual Broadcast 2018 and is being used with the permission of the presenters.

 

Learning Objectives
After completing this program participants should be able to:
  1. Demonstrate greater awareness of clinician and patient barriers to initiation and intensification of insulin therapy.
  2. Recognize the prevalence and clinical impact of hypoglycemia in special populations at risk.
  3. Discuss the pharmacology and clinical differences between existing and new long-acting and concentrated insulins.
  4. Incorporate new basal and concentrated insulins into clinical practice while minimizing the risk of adverse events.

How to obtain the CME Certificate

  1. Register for the course at www.naceonline.com
  2. View the content.
  3. Complete and submit the post-test and evaluation. A minimum passing score of 70% must be earned on the post-test in order to complete the CME activity.
  4. Print your CME certificate.
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education which includes 0.25 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Speaker
Mark Stolar, MD, serves on the speakers bureau for AstraZeneca.

Contributing Faculty
Rodolfo J. Galindo, MD, faculty, has no relevant financial relationships to disclose

Javier Morales, MD, FACP, FACE, faculty, serves on the speakers bureau and as a consultant for Lilly, Novo Nordisk, Janssen, and Abbott.

Leann Olansky, MD, FACP, FACE, faculty, has no relevant financial relationships to disclose.

Jeff Unger, MD, FAAFP, FACE, faculty, serves as a consultant, researcher and advisory board member for Novo Nordisk, Janssen, and Abbott Diabetes

Activity Planning Committe
Gregg Sherman, MD, has no relationships to disclose.

Josh Killbridge, Medical Writer, has no relationship to disclose.

Harvey C. Parker, Ph.D., has no relationships to disclose.

Michelle Frisch, MPH, has no relationships to disclose.

Sheila Lucas,CWEP, has no relationships to disclose.

Sandy Bihlmeyer, MEd, has no relationship to disclose.

Alan Goodstat, LCSW,has no relationships to disclose.
Commercial Support
This educational activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com. This educational activity is supported by an educational grant from Novo Nordisk Inc.